Sun Pharma Advanced Research Company Ltd
Fundamental Score
Sun Pharma Advanced Research Company Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SPARC across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (29.45%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.
Balanced Promoter Holding (65.67%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Suboptimal ROCE (-297.83%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Margin Pressure Concerns (-163.17%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges. Monitor for operational improvements.
Revenue Contraction (-38.88%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Limited Growth History (-1.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (2.39% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-1.73% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Weak Interest Coverage (-11.81x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-1297.54 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Limited Institutional Interest (FII+DII: 2.81%)
Observation: Low institutional participation may affect liquidity and visibility.
Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Financial Statements
Comprehensive financial data for Sun Pharma Advanced Research Company Ltd
About SPARC
Business Overview
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
Company Details
Key Leadership
SPARC Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Sun Pharma Advanced Research Company Ltd (SPARC)?
As of 08 Feb 2026, 11:51 am IST, Sun Pharma Advanced Research Company Ltd (SPARC) is currently trading at ₹139.16. The stock has a market capitalization of ₹4.36K (Cr).
Is SPARC share price Overvalued or Undervalued?
SPARC is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Sun Pharma Advanced Research Company Ltd share price?
Key factors influencing SPARC's price include its quarterly earnings growth (Sales Growth: -38.88%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Sun Pharma Advanced Research Company Ltd a good stock for long-term investment?
Sun Pharma Advanced Research Company Ltd shows a 5-year Profit Growth of -1.73% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing.
How does Sun Pharma Advanced Research Company Ltd compare with its industry peers?
Sun Pharma Advanced Research Company Ltd competes with major peers in the Pharmaceuticals. Investors should compare SPARC's P/E of 0.00x and ROE of N/A% against the industry averages to determine its competitive standing.
What is the P/E ratio of SPARC and what does it mean?
SPARC has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is SPARC performing according to Bull Run's analysis?
SPARC has a Bull Run fundamental score of 18.3/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SPARC belong to?
SPARC operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Sun Pharma Advanced Research Company Ltd.
What is Return on Equity (ROE) and why is it important for SPARC?
SPARC has an ROE of N/A%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Sun Pharma Advanced Research Company Ltd generates profits from shareholders' equity.
How is SPARC's debt-to-equity ratio and what does it indicate?
SPARC has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is SPARC's dividend yield and is it a good dividend stock?
SPARC offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SPARC grown over the past 5 years?
SPARC has achieved 5-year growth rates of: Sales Growth -1.35%, Profit Growth -1.73%, and EPS Growth 2.39%.
What is the promoter holding in SPARC and why does it matter?
Promoters hold 65.67% of SPARC shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SPARC's market capitalization category?
SPARC has a market capitalization of ₹4358 crores, placing it in the Small-cap category.
How volatile is SPARC stock?
SPARC has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SPARC?
SPARC has a 52-week high of ₹N/A and low of ₹N/A.
What is SPARC's operating profit margin trend?
SPARC has a 5-year average Operating Profit Margin (OPM) of -163.17%, indicating the company's operational efficiency.
How is SPARC's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -38.88% and YoY Profit Growth of 29.45%.
What is the institutional holding pattern in SPARC?
SPARC has FII holding of 1.76% and DII holding of 1.05%. Significant institutional holding often suggests professional confidence in the stock.